Overcoming endocrine resistance in breast cancer: Importance of mTOR inhibition

Expert Review of Anticancer Therapy

Volumn 12, Issue 12, 2012, Pages 1579-1589

  Gnant, Michael ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

breast cancer; endocrine; everolimus; mTOR; resistance; temsirolimus

Indexed keywords

ANALGESIC AGENT; ANASTROZOLE; AROMATASE INHIBITOR; CARBOPLATIN; CORTICOSTEROID; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EVEROLIMUS; EXEMESTANE; FULVESTRANT; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NAVELBINE; NERATINIB; PACLITAXEL; PLACEBO; PROGESTERONE RECEPTOR; RAPAMYCIN; TAMOXIFEN; TEMSIROLIMUS; TRASTUZUMAB;

ADVANCED CANCER; ANEMIA; APOPTOSIS; ARTHRALGIA; ASTHENIA; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER RESISTANCE; CLINICAL TRIAL (TOPIC); DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG INTERMITTENT THERAPY; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FATIGUE; GRAFT REJECTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; KIDNEY CARCINOMA; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PAIN; PANCREATIC NEUROENDOCRINE TUMOR; PERIPHERAL EDEMA; PNEUMONIA; POSTMENOPAUSE; PROGRESSION FREE SURVIVAL; REVIEW; STOMATITIS; SUBEPENDYMAL GIANT CELL ASTROCYTOMA; THROMBOCYTOPENIA; TRIPLE NEGATIVE BREAST CANCER;

ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84871496915     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.138     Document Type: Review

References (58)

1. Chumsri S, Howes T, Bao T, Sabnis G, Brodie A. Aromatase, aromatase inhibitors, and breast cancer. J. Steroid Biochem. Mol. Biol. 125(1-2), 13-22 (2011
2. Mouridsen H, Gershanovich M, Sun Y et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J. Clin. Oncol. 21(11), 2101-2109 (2003
3. Massarweh S, Schiff R. Resistance to endocrine therapy in breast cancer: Exploiting estrogen receptor/growth factor signaling crosstalk. Endocr. Relat. Cancer 13(Suppl. 1), S15-S24 (2006
4. Landsman-Blumberg P, Namjoshi M, Thomson E, Johnson W. Real-world aromatase inhibitor use and failure in women with metastatic ER+/HER2- breast cancer. Presented at: 48th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 1-5 June 2012 (Abstract 593
5. Dodwell D, Wardley A, Johnston S. Postmenopausal advanced breast cancer: Options for therapy after tamoxifen and aromatase inhibitors. Breast 15(5), 584-594 (2006
6. Jelovac D, Sabnis G, Long BJ, Macedo L, Goloubeva OG, Brodie AM. Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole. Cancer Res. 65(12), 5380-5389 (2005
7. Shi L, Dong B, Li Z et al. Expression of ER-{α}36, a novel variant of estrogen receptor {α}, and resistance to tamoxifen treatment in breast cancer. J. Clin. Oncol. 27(21), 3423-3429 (2009
8. Sabnis GJ, Jelovac D, Long BJ, Schayowitz A, Belosay A, Brodie AMH. Mammalian target of rapamycin (mTOR as a target in human breast cancer cells that have acquired resistance to aromatase inhibitor letrozole. Presented at: 97th Annual Meeting of the American Association for Cancer Research. Washington, DC, USA, 1-5 April 2006 (Abstract 2316
9. Schiff R, Reddy P, Ahotupa M et al. Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J. Natl Cancer Inst. 92(23), 1926-1934 (2000
10. Zhou Y, Yau C, Gray JW et al. Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer 7, 59 (2007
11. Chen D, Washbrook E, Sarwar N et al. Phosphorylation of human estrogen receptor α at serine 118 by two distinct signal transduction pathways revealed by hosphorylation-specific antisera. Oncogene 21(32), 4921-4931 (2002
12. Kato S, Endoh H, Masuhiro Y et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270(5241), 1491-1494 (1995
13. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H. Phosphatidylinositol 3-kinase/ AKT-mediated activation of estrogen receptor α: A new model for anti-estrogen resistance. J. Biol. Chem. 276(13), 9817-9824 (2001
14. Miller TW, Hennessy BT, González- Angulo AM et al. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J. Clin. Invest. 120(7), 2406-2413 (2010
15. Santen RJ, Song RX, Zhang Z et al. Adaptive hypersensitivity to estrogen: Mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment. J. Steroid Biochem. Mol. Biol. 95(1-5), 155-165 (2005
16. Tokunaga E, Kimura Y, Mashino K et al. Activation of PI3K/Akt signaling and hormone resistance in breast cancer. Breast Cancer 13(2), 137-144 (2006
17. Yue W, Fan P, Wang J, Li Y, Santen RJ. Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells. J. Steroid Biochem. Mol. Biol. 106(1-5), 102-110 (2007
18. Bergh J, Jönsson PE, Lidbrink EK et al. FACT: An open-label randomized Phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J. Clin. Oncol. 30(16), 1919-1925 (2012
19. Dodwell D, Coombes G, Bliss JM, Kilburn LS, Johnston S; SoFEA Trial Management Group. Combining fulvestrant (Faslodex) with continued oestrogen suppression in endocrine-sensitive advanced breast cancer: The SoFEA trial. Clin. Oncol. (R. Coll. Radiol.) 20(5), 321-324 (2008
20. Johnston S, Kilburn LS, Ellis P et al. Fulvestrant alone or with concomitant anastrozole vs exemestane following progression on non-steroidal aromatase inhibitor: First results of the SoFEa trial (CRUKE/03/021 & CRUK/09/007) (ISRCTN44195747). Presented at: 8th European Breast Cancer Conference (EBCC Vienna, Austria, 21-24 March 2012 (Abstract 2LBA
21. Mehta RS, Barlow WE, Albain KS et al. Combination anastrozole and fulvestrant in metastatic breast cancer. N. Engl. J. Med. 367(5), 435-444 (2012
22. Afinitor (everolimus), prescribing information. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA (2012
23. Rapamune (sirolimus), prescribing information. Wyeth Pharmaceuticals Inc., a division of Pfizer Inc., Philadelphia, PA, USA (2011
24. Dobashi Y, Watanabe Y, Miwa C, Suzuki S, Koyama S. Mammalian target of rapamycin: A central node of complex signaling cascades. Int. J. Clin. Exp. Pathol. 4(5), 476-495 (2011
25. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 124(3), 471-484 (2006
26. Alers S, Löffler AS, Wesselborg S, Stork B. Role of AMPK-mTOR-Ulk1/2 in the regulation of autophagy: Cross talk, shortcuts, and feedbacks. Mol. Cell. Biol. 32(1), 2-11 (2012
27. Murakami M, Ichisaka T, Maeda M et al. mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells. Mol. Cell. Biol. 24(15), 6710-6718 (2004
28. Mondesire WH, Jian W, Zhang H et al. Targeting mammalian target of rapamycin synergistically enhances chemotherapyinduced cytotoxicity in breast cancer cells. Clin. Cancer Res. 10(20), 7031-7042 (2004
29. Treeck O, Wackwitz B, Haus U, Ortmann O. Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells. Gynecol. Oncol. 102(2), 292-299 (2006
30. Sadler TM, Gavriil M, Annable T, Frost P, Greenberger LM, Zhang Y. Combination therapy for treating breast cancer using antiestrogen, ERA-923, and the mammalian target of rapamycin inhibitor, temsirolimus. Endocr. Relat. Cancer 13(3), 863-873 (2006
31. Boulay A, Rudloff J, Ye J et al. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin. Cancer Res. 11(14), 5319-5328 (2005
32. Zhu Y, Zhang X, Liu Y et al. Antitumor effect of the mTOR inhibitor everolimus in combination with trastuzumab on human breast cancer stem cells in vitro and in vivo. Tumour Biol. 33(5), 1349-1362 (2012
33. García-García C, Ibrahim YH, Serra V et al. Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy. Clin. Cancer Res. 18(9), 2603-2612 (2012
34. Beeram M, Tan QT, Tekmal RR, Russell D, Middleton A, DeGraffenried LA. Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. Ann. Oncol. 18(8), 1323-1328 (2007
35. Kim D, Chung J. Akt: Versatile mediator of cell survival and beyond. J. Biochem. Mol. Biol. 35(1), 106-115 (2002
36. Baselga J, Semiglazov V, van Dam P et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J. Clin. Oncol. 27(16), 2630-2637 (2009
37. Carpenter JT, Roche H, Campone M et al. Randomized 3-arm, Phase 2 study of temsirolimus (CCI-779) in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer. J. Clin. Oncol. 23(Suppl. 16), Abstract 564 (2005
38. Chow LWC, Sun Y, Jassem J et al. Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer. Presented at: 29th Annual San Antonio Breast Cancer Conference. San Antonio, TX, USA, 14-17 December 2006 (Abstract 6091
39. Bachelot T, Bourgier C, Cropet C et al. Randomized Phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human pidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: A GINECO Study. J. Clin. Oncol. 30(22), 2718-2724 (2012
40. Baselga J, Campone M, Piccart M et al. Everolimus in postmenopausal hormonereceptor- positive advanced breast cancer. N. Engl. J. Med. 366(6), 520-529 (2012
41. Hortobagyi GN, Piccart M, Rugo H et al. Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 Phase III trial. Presented at: 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 6-10 December 2011 (Abstract S3-7
42. Piccart M, Noguchi S, Pritchard KI et al. Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 Phase III trial. Presented at: 48th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 1-5 June 2012 (Abstract 559
43. Bhattacharyya GS, Biswas J, Singh JK et al. Reversal of tamoxifen resistance (hormone resistance) by addition of sirolimus (mTOR inhibitor) in metastatic breast cancer. Eur. J. Cancer 47, Abstract 16LBA (2011
44. Gajria D, King T, Pannu H et al. Combined inhibition of mTORC1 with temsirolimus and HER2 with neratinib: A Phase I/II study in patients with metastatic HER2-amplified or triple-negative breast cancer. Presented at: 34th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 4-8 December 2011 (Abstract PD09-08
45. Jerusalem G, Fasolo A, Dieras V et al. Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer. Breast Cancer Res. Treat. 125(2), 447-455 (2011
46. Morrow PK, Wulf GM, Ensor J et al. Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J. Clin. Oncol. 29(23), 3126-3132 (2011
47. Andre F, Campone M, O'Regan R et al. Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J. Clin. Oncol. 28(34), 5110-5115 (2010
48. Hurvitz S, Andre F, Burris H et al. BOLERO-1: A randomized, Phase III, double-blind, placebo-controlled multicenter trial of everolimus in combination with trastuzumab and paclitaxel as first-line therapy in women with HER2-positive (HER2+), locally advanced or metastatic breast cancer (BC). Presented at: 48th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 1-5 June 2012 (Abstract TPS648
49. Alexander W. Meeting Highlights: San Antonio Breast Cancer Symposium. P.T. 36(3), 156-158 (2011
50. Gnant M, Hortobagyi G, Rugo HS et al. Everolimus added to exemestane reduced bone turnover marker levels and disease progression in bone in postmenopausal omen with advanced breast cancer: Updated results from the BOLERO-2 trial. Presented at: 8th European Breast Cancer Conference. Vienna, Austria, 21-24 March 2012 (Abstract 3LBA
51. Buckner JC, Forouzesh B, Erlichman C et al. Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer. Invest. New Drugs 28(3), 334-342 (2010
52. Tabernero J, Rojo F, Calvo E et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: A Phase I tumor pharmacodynamic study in patients with advanced solid tumors. J. Clin. Oncol. 26(10), 1603-1610 (2008
53. Gomez-Fernandez C, Garden BC, Wu S, Feldman DR, Lacouture ME. The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: A systematic review of the literature and meta-analysis. Eur. J. Cancer 48(3), 340-346 (2012
54. Porta C, Osanto S, Ravaud A et al. Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur. J. Cancer 47(9), 1287-1298 (2011
55. Eisen T, Sternberg CN, Robert C et al. Targeted therapies for renal cell carcinoma: Review of adverse event management strategies. J. Natl. Cancer Inst. 104(2), 93-113 (2012
56. Albiges L, Chamming's F, Duclos B et al. Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma. Ann. Oncol. 23(8), 1943-1953 (2012
57. European Medicines Agency. Summary of opinion (post authorisation: Afinitor June 2012
58. Hurvitz SA, Hu Y, O'Brien N, Finn RS. Current approaches and future directions in the treatment of HER2-positive breast cancer. Cancer Treat. Rev. doi:10.1016/j. ctrv.2012.04.008 (2012) (Epub ahead of print)